Lumos Pharma Inc

Lumos Pharma — Technical Presentation (June 2023)

42 slides from Lumos Pharma's technical presentation, Jun 21, 2023

  1. Slide 1: KOL Event Response to LUM-201 in Moderate PGHD

    1 KOL Event Response to LUM-201 in Moderate PGHD Fernando Cassorla, MD and Michael Tansey, MD June 21, 2023

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made

  3. Slide 3: Agenda

    3 Agenda • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Michael Tansey, MD, University of Iowa • Fernando Cassorla, MD, University of Chile

  4. Slide 4: Key Opinion Leaders in the Field of Pediatric Endocrinology

    4 Key Opinion Leaders in the Field of Pediatric Endocrinology Michael Tansey, MD is currently Clinical Professor, Dept. of Pediatrics, Division of Pediatric Endocrinology and Diabetes, University of Iowa, Iowa City, a position he has held since 2012, having first served as Clinical Assistant Profess

  5. Slide 5: Overview

    5 Overview Lead asset targeting children with growth disorders Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for growth hormone deficiency (GHD) disorders • LUM-201 acts within natural endocrine pathway, differentiated from inje

  6. Slide 6: Phase 2 OraGrowtH Trials – Primary Outcome Data Due Q4

    6 Phase 2 OraGrowtH Trials – Primary Outcome Data Due Q4 2023 • Dose-finding multi-site study • N = 82 PEM+ PGHD subjects randomized • 4 treatment arms o 0.8 mg/kg/day LUM-201 o 1.6 mg/kg/day LUM-201 o 3.2 mg/kg/day LUM-201 o Standard dose rhGH control arm • Primary outcome at 6 months on therapy •

  7. Slide 7: Historical rhGH Data Set Expectations for Growth on Therapy in Moderate PGHD

    7 Historical rhGH Data Set Expectations for Growth on Therapy in Moderate PGHD rhGH 0204 rhGH GeNeSIS1 rhGH iPGHD2 rhGH KIGS3 0 4 8 12 16 20 n=3075 8.58 n=100 8.30 n=433 8.29 n=11 8.80 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) • GeNeSIS1, iPGHD2, and KIGS3 datasets demonstrating AHV at

  8. Slide 8: Interim OraGrowtH210 Data: LUM-201 Growth in Line with Historical Norms

    8 Interim OraGrowtH210 Data: LUM-201 Growth in Line with Historical Norms rhGH growth not in line with historical norms for moderate PGHD Sources: 1 Blum et al JES 2021, 2 Lechuga-Sancho et al JPEM 2009, 3 Ranke et al JCEM 2010, 4 Bright et al JES 2021. Historical AHVs at 6 or 12 mos on injectable r

  9. Slide 9: OraGrowtH210 Trial Baseline Characteristics at 50% & 100% Enrollment

    9 OraGrowtH210 Trial Baseline Characteristics at 50% & 100% Enrollment LUM-201 1.6 mg Mean (SD) N=10 rhGH Mean (SD) N=10 LUM-201 1.6 mg Mean (SD) N=22 rhGH Mean (SD) N=20 Age (months) 99.3 (28.3) 90.3 (26.7) 95.2 (27.3) 91.4 (23.3) Height (cm) 114.6 (9.6) 111.6 (11.9) 113.0 (11.0) 112.3 (10.5) Heigh

  10. Slide 10: Expectations for a Registrational Phase Trial in Moderate PGHD

    10 Expectations for a Registrational Phase 3 Trial in Moderate PGHD Based on recent peer registrational trials in PGHD Projected Design for Phase 3 Trial Anticipated Endpoints for Phase 3 Trial • International multi-center trial • ~200 PEM-positive (PEM+) moderate idiopathic PGHD subjects* • Subject

  11. Slide 11: ENDO 2023 – Session OR21-03: Dose Responsiveness of LUM-201

    ENDO 2023 – Session OR21-03 Dose Responsiveness of LUM-201 as Measured by Acute GH Response and IGF-1 and Annualized Height Velocity (AHV) Measured at 6 Months in the Interim Analysis of the OraGrowtH212 Study in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD) 1University of Chile, Santiago,

  12. Slide 12: Disclosure

    Dr. Cassorla is an investigator for clinical studies with LUM-201 at the University of Chile (Sponsor - Lumos Pharma, Inc.) and has previously acted as a consultant for Debiopharm, Pfizer, Merck, Novo Nordisk and Sandoz. LUM-201 is an investigational compound and is not approved for use by the FDA o

  13. Slide 13: LUM-201 (ibutamoren) – Mechanism of Action

    Oral LUM-201 is a growth hormone (GH) secretagogue • Acts as a durable agonist of GH Secretagogue Receptor (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to increase the amplitude of endogenous, pulsatile GH secretion over 24 hours2,3 • Another differentiating feature vs rhGH is the n

  14. Slide 14: Phase 2 Pulsatility and PK/PD Study Design

    Phase 2- Pulsatility and PK/PD Study Design Naive Idiopathic PGHD Patients Screening Baseline 6 months Height Height IGF-1 IGF-1 q10m x 12h GH q10m 12h GH Standard GH stimulation tests Peak GH to single LUM-201 PEM dose n = 11 LUM-201-3.2mg/kg/day n = 11 LUM-201-1.6 mg/kg/day R Dosing to near Adult

  15. Slide 15: Questions

    Questions 1. Does LUM-201 dose-dependently augment endogenous GH pulses in patients with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD)? 2. Will increased amplitude of GH pulsatility and increase in IGF-1 within normal range improve height velocity? 3. Is the effect on AHV durable out to 12

  16. Slide 16: Baseline Demographics

    Baseline Demographics Subjects N=15 1.6 mg N=8 3.2 mg N=7 Mean (SD) Age (mos) 96.9 (11.9) 95.0 (22.7) Height (cm) 115.2 (4.57) 113.1(9.97) Height SDS -2.12 (0.29) -2.34 (0.45) IGF-1 SDS -1.1 (0.535) -0.8 (0.377) MPH (cm) 161.8 (6.98) 160.82 (5.73) MPH SDS Δ 0.73 (0.47) 0.81 (0.43) BA Delay (yrs) 1.5

  17. Slide 17: AHV Before and After 6 Months of LUM-201 Treatment

    AHV Before and After 6 months of LUM-201 Treatment 17 6-month observations: • LUM-201 raised the AHV (growth rate) from baseline after 6 months on therapy for both the 1.6 mg/kg cohort (p = 0.0006) and the 3.2 mg/kg cohort (p < 0.0001) • No statistical difference exists between the two cohorts at ea

  18. Slide 18: Durable Response After 12 Months of LUM-201 Administration

    Durable Response After 12 Months of LUM-201 Administration Mean AHV’s in OraGrowtH212 Trial 1Ranke, et.al. 2010 JCEM 95(3):1229-1237.18

  19. Slide 19: Height Velocity During Daily rhGH Therapy

    First year Second year Severe PGHD Moderate PGHD Height Velocity During Daily rhGH Therapy Ranke, et.al. 2010 JCEM 95(3):122919

  20. Slide 20: IGF-1 Values: Treatment with LUM-201 Increased Serum IGF-1

    20 IGF-1 Values: Treatment with LUM-201 Increased Serum IGF-1 Concentration and IGF-1 SDS Values Conclusions : • There is a significant increase in IGF-1 levels that remains within the normal range • Based on the MOA of LUM-201, these data support the physiological IGF-1 feedback

  21. Slide 21: IGF-1, GH Pulsatility, Height Velocity: Patient A

    IGF-1, GH Pulsatility, Height Velocity: Patient A 1.6 mg/kg/day 0 200 400 600 800 0 2 4 6 8 10 Patient A Time (min) S e ru m G ro w th H o rm o n e (n g /m l) 21 Patient A Baseline GH Baseline 6 months LUM-201 1.6 mg/kg/d IGF-1 (ng/ml) 179.3 Q10m 12h GH AUC0-12 (ng*hr/ml) 798.8 Height velocity (cm/y

  22. Slide 22: Patient A Baseline & LUM-201 GH

    0 200 400 600 800 0 2 4 6 8 10 Patient A Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Month 6 Baseline 6 months LUM-201 1.6 mg/kg/d IGF-1 (ng/ml) 179.3 289 % change from baseline** 61% Q10m 12h GH AUC0-12 (ng*hr/ml) 798.8 1064.1 % change from baseline** 33% Height velocity (cm/yr)

  23. Slide 23: IGF-1, GH Pulsatility, Height Velocity: Patient B

    0 200 400 600 800 0 1 2 3 4 5 Patient B Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline 6 months LUM-201 3.2 mg/kg/d IGF-1 (ng/ml) 48 Q10m 12h GH AUC0-12 (ng*hr/ml) 252.9 Height velocity (cm/yr) 4.4 IGF-1, GH Pulsatility, Height Velocity: Patient B 3.2 mg/kg/day 23 Patient B Baseline

  24. Slide 24: Patient B Baseline & LUM-201 GH

    0 200 400 600 800 0 1 2 3 4 5 Patient B Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Month 6 Baseline 6 months LUM-201 3.2 mg/kg/d IGF-1 (ng/ml) 48 111 % change from baseline** 131% Q10m 12h GH AUC0-12 (ng*hr/ml) 252.9 481.8 % change from baseline** 91% Height velocity (cm/yr) 4.4

  25. Slide 25: Interim Analysis Safety Profile

    Interim Analysis Safety Profile 25 Safety Conclusion: • At time of interim analysis, LUM-201 was well tolerated and showed no significant safety signals Safety Profile: • No treatment-related Serious Adverse Events (SAEs) or Severe AEs • No meaningful safety signals observed in either laboratory val

  26. Slide 26: Questions

    Questions 1. Does LUM-201 dose-dependently augment endogenous GH pulses in patients with idiopathic Pediatric Growth Hormone Deficiency (iPGHD)? 2. Will increased amplitude of GH pulsatility, driving increased IGF-1, improve height velocity? 3. Is the effect on AHV durable out to 12 months? 26

  27. Slide 27: Conclusions

    Sources: 1 Blum et al JES 2021, 2 Ranke et al JCEM 2010 . 27 • Based on Interim Analysis data, OraGrowtH212 data demonstrates that growth acceleration is durable through 12 months in our study population, pre-pubertal, treatment naïve PGHD patients. • No statistical difference exists between the coh

  28. Slide 28: University of Chile, Santiago Pediatric Team

    University of Chile, Santiago Institute of Maternal and Child Research Pediatric Team 28 28

  29. Slide 29: ENDO 2023 – Session OR21-06: Combined Analysis Interim Analysis Data

    ENDO 2023 – Session OR21-06 Growth Response of Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data Michael Tansey, MD University of Iowa, Pediatric Endocrinology Iowa City, Iowa 29

  30. Slide 30: Disclosure

    Dr. Tansey is an investigator for clinical studies with LUM-201 at the University of Iowa (Sponsor - Lumos Pharma, Inc.). There are no additional disclosures for this presentation. LUM-201 is an investigational compound and is not approved for use by the FDA or any other regulatory agency. Some of t

  31. Slide 31: Abstract Contributors

    Abstract Contributors Andrew Dauber, MD, MMSc, Children’s National Hospital, Washington, DC, United States; Beata Wikiera, MD, PhD, Klinika Endokrynologii i Diabetologii Wieku Rozwojowego UM, Wroclaw, N/A, Poland; Beata Pyrzak, MD, Department of Pediatric and Endocrinology Medical University of Wars

  32. Slide 32: Abstract Contributors

    Abstract Contributors Fernando Cassorla, MD, Institute of Maternal and Child Research, University of Chile, Santiago, Chile Rossana Román, MD, Institute of Maternal and Child Research, University of Chile, Santiago, Chile Michael L Johnson, PhD, Emeritus University of Virginia, Charlottesville, Virg

  33. Slide 33: Objective of the Presentation

    Objective of the Presentation Report the growth response analyzing the combined interim analysis (IA) data from two Phase 2 trials studying LUM-201 at two different doses (1.6 mg/kg/day or 3.2 mg/kg/day). IA data from both studies were combined and analyzed for calculated annualized height velocity

  34. Slide 34: LUM-201 (ibutamoren) – Mechanism of Action

    • Oral LUM-201 is a growth hormone (GH) secretagogue • Acts as a durable agonist of GH Secretagogue Receptor (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to increase the amplitude of endogenous, pulsatile GH secretion over 24 hours2,3 • Another differentiating feature vs rhGH is the

  35. Slide 35: Single Stim Dose of LUM-201 Identifies PEM+ Responders

    Single Stim Dose of LUM-201 Identifies PEM+ Responders 1 Blum 2021 JES Responders to LUM-201 Non-Responders to LUM-201 Predictive Enrichment Marker Positive (PEM+) • Baseline IGF-1 > 30 ng/ml • Stim LUM-201 peak GH ≥ 5 ng/ml • Functional but reduced HP-GH axis Predictive Enrichment Marker Negative (

  36. Slide 36: Phase 2 Dose Finding Study Design

    Phase 2 - Dose Finding Study Design Naive Idiopathic PGHD Patients Screening 6, 9, 12, 24 months Height IGF-1 Standard GH stimulation tests Peak GH ≥ 5 ng/ml to single LUM-201 dose Long-term extension study n = ~20 LUM-201-3.2mg/kg/day n = ~20 LUM-201-1.6 mg/kg/day R n = ~20 LUM-201-0.8mg/kg/day n =

  37. Slide 37: Phase 2 Pulsatility and PK/PD Study Design

    Phase 2 - Pulsatility and PK/PD Study Design Naive Idiopathic PGHD Patients Screening Baseline 6 months Height Height IGF-1 IGF-1 q10m x 12h GH q10m 12h GH Standard GH stimulation test Peak GH to single LUM-201 PEM dose n = 11 LUM-201-3.2mg/kg/day n = 11 LUM-201-1.6 mg/kg/day R Dosing to near Adult

  38. Slide 38: Baseline Demographics for OraGrowtH210 and OraGrowtH212

    Baseline Demographics for OraGrowtH210 and OraGrowtH212 Subjects N=20 1.6 mg N=10 3.2 mg N=10 Mean (SD) Age (mos) 99.3 (28.3) 96.1 (21.7) Height (cm) 114.6 (9.6) 113.8 (8.8) Height SDS -2.35 (0.62) -2.30 (0.48) IGF-1 SDS -1.17 (0.72) -1.39 (0.61) MPH (cm) 166.98 (7.15) 166.20 (8.06) MPH SDS Δ 1.76 (

  39. Slide 39: Annualized Height Velocity of Doses Show Durable Response from 6-12 Months

    Annualized Height Velocity of 2 Doses Show Durable Response from 6-12 Months Interim Analysis (IA) Results • Interim data demonstrate LUM- 201 produces durable AHV response from 6 to 12 months in moderate PGHD • LUM-201 at both 1.6 mg/kg and 3.2 mg/kg produces a clinically meaningful increase in AHV

  40. Slide 40: IA Safety Data from Combined Trials

    1.6 mg/kg 3.2 mg/kg N =33 N=33 Number of AEs 105 110 Subjects with AE (%) 29 (87.9%) 30 (90.9%) Treatment Related AEs * 17 19 Subjects with Treatment Related AEs (%) 12 (36.4%) 13 (39.4%) Subjects with SAEs (%) 0 (0%) 0 (0%) IA Safety Data from Combined Trials Interim Analysis (IA) Results • No trea

  41. Slide 41: Conclusion

    • As the growth velocity was comparable for the two doses of oral LUM-201, this analysis of the combined IA data suggests 1.6 mg/kg/day as the optimal dose for the Phase 3 trial, as doubling the dose appeared to offer no meaningful improvement in efficacy. • Final dose determination will await final

  42. Slide 42: Questions & Answers

    42 Questions & Answers lumos

Lumos Pharma — Technical Presentation (June 2023) on 6ix